Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb

Xiangguo Qiu, Jonathan Audet, Gary Wong, Lisa Fernando, Alexander Bello, Stéphane Pillet, Judie B. Alimonti, Gary P. Kobinger

Research output: Contribution to journalArticlepeer-review

88 Scopus citations

Abstract

Ebola virus (EBOV) is one of the most lethal filoviruses, with mortality rates of up to 90% in humans. Previously, we demonstrated 100% and 50% survival of EBOV-infected cynomologus macaques with a combination of 3 EBOV-GP-specific monoclonal antibodies (ZMAb) administered at 24 or 48 hours post-exposure, respectively. The survivors demonstrated EBOV-GP-specific humoral and cell-mediated immune responses. In order to evaluate whether the immune response induced in NHPs during the ZMAb treatment and EBOV challenge is sufficient to protect survivors against a subsequent exposure, animals that survived the initial challenge were rechallenged at 10 or 13 weeks after the initial challenge. The animals rechallenged at 10 weeks all survived whereas 4 of 6 animals survived a rechallenge at 13 weeks. The data indicate that a robust immune response was generated during the successful treatment of EBOV-infected NHPs with EBOV, which resulted in sustained protection against a second lethal exposure.

Original languageEnglish (US)
Article number3365
JournalScientific reports
Volume3
DOIs
StatePublished - Nov 28 2013
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb'. Together they form a unique fingerprint.

Cite this